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Abstract 
Background: Patients with type 2 diabetes (T2D) have a substantial increased risk for cardiovascular (CV) disease 
and associated mortality than those without diabetes. Dulaglutide is a once-weekly glucagon-like peptide-1 receptor 
agonist that is approved for treatment of T2D.
Methods: This meta-analysis evaluates the CV risk in patients with T2D treated with dulaglutide in 9 randomized 
safety and efficacy trials. Mean (median) treatment duration was 333 (358) days. Reported CV events were indepen-
dently adjudicated by a treatment-blinded clinical endpoint committee. The primary measure was a 4-component 
major adverse CV event (4-component MACE) composite endpoint of death due to CV causes, nonfatal myocardial 
infarction (MI), nonfatal stroke, or hospitalization for unstable angina. Additional pre-specified endpoints included 
adjudicated coronary revascularizations, hospitalization for heart failure, and all-cause mortality. A Cox proportional 
hazards regression model (stratified by study) was used to estimate the hazard ratio (HR) and confidence interval (CI). 
Tests of treatment effects for the primary endpoint were conducted at a 2-sided alpha level of 0.0198 and a corre-
sponding 98.02 % CI was calculated. Statistical heterogeneity between the strata (studies) was tested by including in 
the Cox model an interaction term between treatment and strata.
Results: The analysis included 6010 randomized patients [dulaglutide: 3885; comparator therapy (active or placebo): 
2125]; cumulative exposure to dulaglutide or comparator therapy was 3941 and 2223 patient-years, respectively. The 
demographic and baseline CV disease characteristics were similar across groups. Twenty-six (0.67 %) patients in the 
dulaglutide group versus 25 (1.18 %) in the comparator group experienced a primary 4-component MACE (HR 0.57; 
adjusted 98.02 % CI 0.30, 1.10). Results for the 3-component MACE (composite endpoint of death due to CV causes, 
nonfatal MI or stroke), 6-component MACE (composite endpoint of death due to CV causes, nonfatal MI or stroke, 
hospitalization for unstable angina or heart failure, or coronary revascularizations) and all-cause mortality were con-
sistent with the primary analysis (HR < 1.0 for all).
Conclusions: These results suggest that dulaglutide does not increase the risk of major CV events in T2D patients. 
The ongoing CV outcomes study, Researching CV Events with a Weekly Incretin in Diabetes (REWIND), will further 
assess CV safety of dulaglutide.
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Background
Patients with type 2 diabetes (T2D) have a substantially 
increased lifetime risk for cardiovascular (CV) disease 
and associated death; older persons with T2D may have 
twofold to fourfold greater risk than those without diabe-
tes [1–5]. Concerns have been raised regarding the effects 
of different anti-diabetic medications on CV safety [6], 
therefore, regulatory agencies now require that the CV 
safety of anti-diabetic medications be thoroughly studied 
prior to regulatory review [Food and Drug Administra-
tion (FDA) 2008; Committee for Medicinal Products for 
Human Use (CHMP) 2012] [7, 8]. It is advised to per-
form a meta-analysis of the clinical development data to 
demonstrate that the upper bound of the 95 % confidence 
interval (CI) of the hazard ratio (HR) for major adverse 
CV events in the treatment group is <1.8 compared to 
the comparator therapy (control) group. Additionally, it is 
advised to demonstrate that the upper bound of the 95 % 
CI of the HR is <1.3 in a dedicated CV outcomes study.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) 
significantly decrease hemoglobin A1c (HbA1c) via stim-
ulating glucose-dependent insulin secretion, suppressing 
glucagon, delaying gastric emptying, and reducing appe-
tite and food intake [9]. Early long-term glycemic control 
may decrease macrovascular complications in T2D [10, 
11], therefore, treatment with GLP-1 RAs may modify 
CV risk. In addition to glycemic control, treatment with 
GLP-1 RAs exerts additional effects that may potentially 
alter the CV risk, including a decrease in body weight and 
a small decrease in systolic blood pressure (SBP), but with 
a small increase in heart rate.
Dulaglutide, a once-weekly long-acting GLP-1 RA, 
exhibits GLP-1 mediated effects [12, 13]. The Assessment 
of Weekly AdministRation of dulaglutide in Diabetes 
(AWARD) clinical development program demonstrated 
that treatment with dulaglutide improved glycemic con-
trol and caused significant decreases in HbA1c when 
compared to placebo or active comparators [14–23]. 
Treatment with dulaglutide was also associated with 
effects that may potentially alter CV risk including weight 
loss (or attenuation of weight gain) [14–23] and a small 
decrease in SBP, but with a small increase in heart rate 
[17]. This pre-specified CV meta-analysis evaluated CV 
risk in the dulaglutide clinical development program and 
included prospectively blinded adjudicated CV events 
from 9 controlled clinical studies, using different com-
parators and background medications, and encompass-
ing a broad spectrum of the T2D population.
Methods
Studies
This CV meta-analysis included adjudicated CV events 
from a total of 9 clinical trials [14–23]; 4 Phase 2 studies 
(study durations: 12–26  weeks) and 5 Phase 3 studies 
(study durations: 52–104 weeks) (Table 1). A total of 3885 
patients randomized to dulaglutide and a total of 2125 
patients randomized to comparator therapy (placebo or 
active comparator) are included in this analysis. The dose 
of dulaglutide in the Phase 2 studies and the dose-finding 
portion of AWARD-5 ranged from 0.1 to 3 mg and it was 
0.75 and 1.5 mg in the Phase 3 studies. While all 4 Phase 
2 studies were placebo-controlled, comparator agents in 
the 5 Phase 3 studies included placebo, sitagliptin, exena-
tide, insulin glargine, or metformin. After completing the 
study treatment period, patients in these studies discon-
tinued the assigned therapies and did not continue treat-
ment in safety follow-up periods or in separate protocols.
As previously indicated in original publications for 
each clinical trial, all patients provided written informed 
consent before initiation of study procedures. Institu-
tional review boards of all participating sites approved 
the protocol. Trials were conducted in compliance with 
Good Clinical Practice guidelines and the ethical princi-
ples stated in the Declaration of Helsinki [14–23].
The Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) criteria for reporting 
meta-analyses [24] were followed; however, this meta-
analysis was based on a pre-specified meta-analysis plan 
specifying that the analysis would include Phase 2 and 
Phase 3 studies from the dulaglutide clinical develop-
ment program. Therefore, many of the PRISMA criteria 
related to reporting literature search strategy and criteria 
used for inclusion or exclusion of studies did not apply 
for this pre-specified meta-analysis.
This meta-analysis was performed on patient-level data 
from the included studies and all CV events were pro-
spectively collected and adjudicated based on a common 
charter and based on the same event definitions. As pro-
spectively defined, data from dulaglutide clinical phar-
macology studies were not included in the meta-analysis 
due to their shorter durations of exposure (<6  weeks). 
There were no investigator-reported events of CV-related 
death, non-fatal stroke, non-fatal MI, or hospitalization 
for unstable angina in these studies.
Analysis population
Common inclusion criteria in the Phase 3 trials included 
a diagnosis of inadequately controlled T2D, age 
≥18  years, a baseline HbA1c of 6.5–11.0  % (depending 
on specific study), previous treatment with diet and exer-
cise alone or ongoing treatment with one or more oral 
anti-diabetic medications (OAM), stable weight (±5  %) 
for at least 3  months prior to screening, and a written 
informed consent. Females of childbearing potential were 
required to agree to use a reliable method of birth control 
during the study. Patients with recent CV events were 
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generally excluded [for example, myocardial infarction 
(MI), stroke, or heart failure within 2–6 months]; Phase 
2 studies and AWARD-5 study excluded patients with 
heart failure; AWARD-2 and AWARD-4 only excluded 
New York Heart Association (NYHA) class III or class IV 
heart failure; in addition, NYHA class II heart failure was 
also excluded in AWARD-1 due to concomitant admin-
istration of pioglitazone; and AWARD-3 only excluded 
NYHA class IV heart failure. The majority of studies 
excluded patients with serum creatinine ≥1.5  mg/dL 
(male) or ≥1.4  mg/dL (female), or creatinine clearance 
<60  mL/min. However, 3 studies included patients with 
higher serum creatinine levels or a lower estimated glo-
merular filtration rate (eGFR) if not contraindicated with 
concomitant medications; therefore, some patients with 
a eGFR < 60 mL/min/1.73 m2 were included in the meta-
analysis [14, 17, 21]. Entry criteria for each study have 
been previously published [14–23]. The analysis popu-
lation included all randomized patients [intent-to-treat 
(ITT) population].
Adjudication
An expert panel, blinded to treatment, [Duke Clini-
cal Research Institute (DCRI), Duke University Medical 
Center] adjudicated the following CV events: death (CV 
and non-CV), acute coronary syndromes (MI and hos-
pitalization for unstable angina), cerebrovascular events 
(stroke and transient ischemic attack), coronary revas-
cularization procedures (coronary artery bypass grafting 
and percutaneous coronary interventions), and hospi-
talization for heart failure. CV events were initially iden-
tified in the 9 included studies by site investigators or 
study personnel during study conduct. Clinical sites were 
responsible for reporting applicable adverse events (AEs) 
and serious adverse events (SAEs), and completing a CV 
event-specific electronic case report form (eCRF). In 
addition, clinical trial databases were queried for specific 
events based on reported AE terms (i.e., MedDRA Pre-
ferred Terms) to identify potentially unreported events. 
CV events were also reported if potentially unreported 
events were identified by monitoring personnel or adju-
dicators. All identified CV events were sent to the DCRI 
clinical event classification (CEC) committee for adjudi-
cation. The CEC committee prospectively adjudicated all 
identified CV events in a blinded manner throughout the 
course of the studies based on pre-specified criteria and a 
pre-defined adjudication process.
Objectives
The primary objective was to compare, for all ran-
domized patients (ITT population), the time from 
randomization to first occurrence of the compos-
ite endpoint of death due to CV causes, nonfatal MI, 
nonfatal stroke, or hospitalization for unstable angina 
[4-component Major Adverse CV Event (MACE)] 
between patients receiving any dose of dulaglutide and 
those receiving comparator therapy (placebo or active 
comparator).
Additional objectives evaluated in this study included:
  • Time from randomization to first occurrence of CV 
events observed with once-weekly dulaglutide versus 
comparator group for each individual component of 
the composite primary endpoint.
Table 1 Phase 2 and Phase 3 dulaglutide studies included in cardiovascular meta-analysis









All (N) Dulaglutide (n)
Phase 2 studies
Dose titrationa [14] 262 196 0.5 → 1.0, 1.0, 
1.0 → 2.0
16 Placebo 2 OAMs
Monotherapya [15] 167 135 0.1, 0.5, 1.0, 1.5 12 Placebo None
Japanese studya [16] 145 108 0.25, 0.5, 0.75 12 Placebo None
ABPM studya [17] 755 505 0.75, 1.5 26 Placebo ≥1 OAM
Phase 3 studies
AWARD-1b [18] 978 559 0.75, 1.5 52 Placebo, exenatide Metformin + pioglitazone
AWARD-2b [19] 810 545 0.75, 1.5 78 Glargine Metformin + glimepiride
AWARD-3a [20] 807 539 0.75, 1.5 52 Metformin None
AWARD-4b [21] 884 588 0.75, 1.5 52 Glargine Lispro ± metformin
AWARD-5a [22, 23] 1202 710 Stage 2: 0.75, 1.5 104 Placebo, sitagliptin Metformin
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  • Time from randomization to first occurrence of the 
3-component MACE endpoint (composite of death 
due to CV causes, nonfatal MI or stroke).
  • Time from randomization to first occurrence of the 
6-component MACE endpoint (composite of death 
due to CV causes, nonfatal MI or stroke, hospitaliza-
tion for unstable angina or heart failure, or coronary 
revascularizations).
  • Time from randomization to first occurrence of hos-
pitalization for heart failure, coronary revasculariza-
tions, and all-cause mortality.
All analyses including the subgroup analysis were con-
ducted on all randomized patients (ITT population). 
Comparisons of dulaglutide versus placebo or active 
comparators, and dulaglutide dose (0.75 or 1.5 mg) ver-
sus placebo or all comparators, were also conducted. Two 
sensitivity analyses were conducted for the per-protocol 
(PP) and completers populations. The PP population was 
defined as all randomized patients who had not discon-
tinued study drug or discontinued from the study, had an 
overall compliance of ≥75 %, and had no important pro-
tocol deviations. The completers population was defined 
as all randomized patients who completed a given study 
regardless of compliance with the protocol.
Statistical analysis
The primary analysis was a Cox proportional hazards 
regression model stratified by study (stratum). The model 
included treatment as a fixed effect with only 2 levels for 
the factor (dulaglutide or comparator groups). Stratifi-
cation by study was used to account for potential differ-
ences in the HRs due to differing durations of the Phase 
2 and 3 trials and differing lengths of follow-up periods. 
Thus, all Phase 2 studies were combined into one stratum; 
each of the Phase 3 AWARD studies (Table 1) formed an 
individual stratum. Since there were no patients with 
an adjudicated primary CV endpoint event in the com-
parator therapy arm of AWARD-3, it was combined with 
AWARD-5 into a single stratum. Statistical heterogeneity 
between the strata was tested by including in the primary 
analysis model an interaction term between treatment 
and strata.
All adjudicated CV events during the treatment peri-
ods and up to 30  days after treatment discontinuation 
were included in the analyses. Unless otherwise noted, 
all tests of treatment effects were conducted at a 2-sided 
alpha level of 0.05 and the CI was calculated at a 2-sided 
95 % level. The pre‐specified meta‐analysis plan included 
a second potential meta‐analysis in case the upper bound 
of the CI for the HR was not <1.8 in the first meta‐analy-
sis; adjustment for multiplicity was performed for the 
primary endpoint using the Pocock alpha-spending 
function to control for type 1 error. Tests of treatment 
effects for the primary endpoint were conducted at a 
2-sided alpha level of 0.0198 and the CI was calculated 
at a 2-sided 98.02 % level. The second meta‐analysis was 
not performed since this first meta-analysis showed the 
upper bound of the 98.02 % CI for the HR was <1.8. All 
tests of interactions between treatment groups and other 
factors were conducted at a 2-sided alpha level of 0.10.
Counts and proportions of patients who experienced a 
primary endpoint and person-years of follow-up for the 
primary endpoint and the incidence rates were calcu-
lated. The incidence rate was calculated by dividing the 
number of patients who developed the event during the 
study period by the event-specific person-years of fol-
low-up. In addition, Kaplan–Meier plots were reported 
for the primary endpoint, as well as Forest plots of the 
results by study (stratum).
Sensitivity analyses consisted of a re-evaluation of the 
primary endpoint for the PP and completers popula-
tions. Subgroup analysis, using the Cox proportional 
hazards regression model, included the subgroups of sex, 
age (≤65, >65  years), duration of diabetes (<5, [5–10], 
>10  years), prior history of CV disease, prior history 
of hypertension, prior history of hyperlipidemia, body 
mass index (BMI; <30, ≥30  kg/m2), baseline HbA1c 
[<8 % (<63.9 mmol/mol), ≥8 % (≥63.9 mmol/mol)], race 
(White, non-White), and geography (North America, 
South America, Europe, Asia Pacific, other). As a sen-
sitivity analysis, MedDRA preferred terms were used to 
categorize AE reflecting CV specific events, regardless 
of their adjudication outcome. All analyses were imple-
mented using SAS® Version 8.2 or higher.
Results
Demographic and baseline disease characteristics
This CV meta-analysis included a total of 6010 patients: 
3885 treated with dulaglutide and 2125 treated with 
comparator therapy (placebo or an active) (Table  2). 
The mean age of patients was 56.1 years and the major-
ity of patients were <65  years of age (81.6  %) and over 
two-thirds were White (68.3  %); 31.1  % of the patients 
were Hispanic or Latino. More than half (55.7  %) were 
enrolled in North America; 21.9 % were enrolled in the 
European Union (EU), 10.1  % in South America, 6.7  % 
in Asia Pacific, and 5.6  % in other regions. The overall 
proportions of males (51.2 %) and females (48.8 %) and 
mean BMI (32.3  kg/m2) were similar in the dulaglutide 
and comparator groups.
The 2 treatment groups were similar with respect to 
most baseline characteristics including mean HbA1c 
(8.1 %), fasting plasma glucose (FPG; 9.04 mmol/L), and 
duration of diabetes (7.9  years) (Table  2). There was 
a small, but significant difference between treatment 
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groups with respect to subgroups defined by baseline 
duration of diabetes (i.e., <5 years for 38.5 % dulaglutide 
vs. 36.0 % comparators; ≥5 to <10 years for 28 % dulaglu-
tide vs. 31 % comparators; p = 0.012).
In addition, baseline CV risk factors or prior CV dis-
ease including history of smoking, hypertension, hyper-
lipidemia, prior stroke/transient ischemic attack, and 
multiple other CV interventions, as well as renal function 
were similar between the two treatment groups (Table 3). 
However, prior MI at baseline was slightly higher for the 
dulaglutide group compared to the comparator group 
(3.4 vs. 2.4 %, p = 0.049) (Table 3).
Effect on primary 4‑component MACE and individual 
components
Results of the meta-analysis showed that 26 (0.67  %) 
patients in the dulaglutide group and 25 (1.18 %) patients 
in the comparator group experienced at least 1 of the 4 
major CV events (death due to CV causes, nonfatal MI, 
nonfatal stroke, or hospitalization for unstable angina) 
(Table 4). The estimated HR for the comparison was 0.57 
with an adjusted 98.02 % CI of 0.30, 1.10 (p = 0.046), indi-
cating that there was no significant difference between 
treatment groups. These data suggest that treatment 
with dulaglutide was not associated with an increase in 
Table 2 Demographic and  other baseline characteristics of  patients included in  the cardiovascular meta-analysis—all 
randomized patients (ITT population)
BMI body mass index, HbA1c glycosylated hemoglobin A1c
a Categorical variables were compared between treatments by Cochran–Mantel–Haenszel test. Continuous variables were compared between treatments by ANOVA 
model adjusting for strata: variable = treatment + stratum








Mean age (years) 56.0 56.2 56.1 0.78
Age group [n (%)] – – – 0.30
 <65 years 1724 (81.1) 3177 (81.8) 4901 (81.6)
 ≥65 years 401 (18.9) 708 (18.2) 1109 (18.5)
Sex [n (%)] – – – 0.27
 Female 1016 (47.8) 1916 (49.3) 2932 (48.8)
 Male 1109 (52.2) 1969 (50.7) 3078 (51.2)
Ethnicity [n (%)] – – – 0.23
 Hispanic or Latino 660 (31.1) 1209 (31.1) 1869 (31.1)
 Not Hispanic or Latino 1463 (68.9) 2676 (68.9) 4139 (68.9)
Raceb [n (%)] – – – 0.27
 American Indian or Alaska Native 135 (6.4) 231 (6.0) 366 (6.1) –
 Asian 271 (12.8) 509 (13.1) 780 (13.0) –
 Black or African American 113 (5.3) 245 (6.3) 358 (6.0) –
 White 1446 (68.1) 2656 (68.4) 4102 (68.3) –
Mean duration of diabetes (years) 8.0 7.9 7.9 0.22
Duration of diabetes – – – 0.01
 <5 years 765 (36.0) 1494 (38.5) 2259 (37.6)
 ≥5 and <10 years 659 (31.0) 1088 (28.0) 1747 (29.1)
 ≥10 years 701 (33.0) 1303 (33.5) 2004 (33.3)
Mean BMI (kg/m2) 32.4 32.3 32.3 0.51
Fasting plasma glucose
 Mean (mmol/L) 9.07 9.01 9.04 0.69
 <5.6 mmol/L [n (%)] 109 (5.2) 200 (5.2) 309 (5.2) 0.79
 ≥5.6 mmol/L [n (%)] 1994 (94.8) 3630 (94.8) 5624 (94.8)
HbA1c
 Mean (%) 8.1 8.1 8.1 0.87
 Mean (mmol/mol) 65.0 65.0 65.0
 <8 % (<63.9 mmol/mol) [n (%)] 1113 (52.6) 2039 (52.6) 3152 (52.6) 0.62
 ≥8 % (≥63.9 mmol/mol) [n (%)] 1005 (47.5) 1838 (47.4) 2843 (47.4)
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the risk of experiencing a 4-component MACE endpoint 
versus comparator therapy. In addition, the upper bound 
of the adjusted 2-sided 98.02 % CI for the HR (1.10) was 
less than the FDA-stipulated limit of 1.8. The treatment 
difference was also consistent across the strata (studies); 
there was no significant interaction between treatment 
and strata (interaction p = 0.598).
The Kaplan–Meier curves for the estimated cumulative 
incidence of the time to first occurrence of the 4-compo-
nent MACE appear to start separating early, with the ear-
liest divergence appearing around 28 weeks of exposure 
to treatment (Fig. 1). A Forest plot of the primary 4-com-
ponent MACE comparing HR values with 98.02 % CIs by 
stratum (study) shows that the HRs for dulaglutide com-
pared to comparator therapy are generally <1.0 which is 
consistent with the overall result (Fig. 2).
There was no significant difference between the two 
treatment groups for the risk of death due to CV causes, 
nonfatal stroke, or hospitalization for unstable angina. 
However, the relative risk of experiencing a nonfatal MI 
was significantly lower in the dulaglutide group com-
pared with the comparator group (estimated HR 0.35; 
adjusted 98.02 % CI [0.13, 0.95; p = 0.014]) (Table 4).
Results of the sensitivity analyses for the primary 
4‑component MACE endpoint
Time-to-event sensitivity analysis results for the PP and 
completers populations (Additional file  1: Tables S1 
and S2, respectively) showed no significant differences 
between the 2 treatment groups with respect to the 
composite 4-component MACE endpoint. A total of 24 
primary 4-component MACE events were reported in 
Table 3 Comparison of cardiovascular risk factors at baseline—all randomized patients (ITT population)
eGFR estimated glomerular filtration rate, HDL high density lipoprotein, LDL low density lipoprotein, MI myocardial infarction, TIA transient ischemic attack, urine ACR 
urinary albumin/creatinine ratio
a Treatments were compared by Cochran–Mantel–Haenszel test. Strata = studies
b Having hyperlipidemia or taking lipid lowering drugs at baseline or having LDL-C ≥160 mg/dL or HDL-C <40 mg/dL or triglycerides ≥200 mg/dL. Missing value was 
set to category ‘No’
c CV risk factors were either collected directly or were identified by searching historical events and pre-existing events at baseline with relevant preferred terms. 
Missing value is set to category ‘No’. History of lower extremity arterial revascularization was not collected, could not be defined, and is missing for the dose titration 
study, the monotherapy study, and AWARD-5 study











Prior MI 51 (2.4) 132 (3.4) 183 (3.0) 0.049
History of unstable angina 34 (1.6) 55 (1.4) 89 (1.5) 0.632
Prior coronary revascularization 65 (3.1) 115 (3.0) 180 (3.0) 0.738
History of stroke or TIA 35 (1.7) 63 (1.6) 98 (1.6) 0.979
History of heart failure 12 (0.6) 16 (0.4) 28 (0.5) 0.284
History of (documented) coronary artery disease 86 (4.1) 189 (4.9) 275 (4.6) 0.163
Has hypertension 1357 (63.9) 2451 (63.1) 3808 (63.4) 0.504
Has hyperlipidemiab 1176 (55.3) 2116 (54.5) 3292 (54.8) 0.296
History of carotid revascularizationc 4 (0.2) 8 (0.2) 12 (0.2) 0.863
History of lower extremity arterial revascularizationc 7 (0.5) 8 (0.3) 15 (0.3) 0.380
History of peripheral vascular diseasec 30 (1.4) 57 (1.5) 87 (1.5) 0.962
History of atrial fibrillationc 30 (1.4) 38 (1.0) 68 (1.1) 0.173
Current smoker 335 (15.9) 551 (14.3) 886 (14.8) 0.101
Current smoker with hypertension and hyperlipidemia 138 (6.5) 217 (5.6) 355 (5.9) 0.161
Kidney function group by eGFR – – – 0.899
 <30 mL/min/1.73 m2 1 (0.1) 2 (0.1) 3 (0.1)
 30 ≤ eGFR < 60 mL/min/1.73 m2 126 (5.9) 228 (5.9) 354 (5.9)
 ≥60 mL/min/1.73 m2 1998 (94.0) 3654 (94.1) 5652 (94.1)
Albuminuria group by urine ACRd – – – 0.433
 <30 mg/g 1566 (76.8) 2811 (77.1) 4377 (77.0)
 30 ≤ Urine ACR ≤ 300 mg/g 395 (19.4) 713 (19.6) 1108 (19.5)
 >300 mg/g 79 (3.9) 121 (3.3) 200 (3.5)
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the PP population; 13 occurred in the dulaglutide group 
and 11 in the comparator group, with no significant dif-
ference between the 2 groups (HR 0.63; 98.02 % CI 0.24, 
1.63; p  =  0.26). Results in the completers population 
were consistent with the PP analysis.
Consistent with the primary comparison, there was 
no significant difference in the time to occurrence of 
the 4-component MACE by dulaglutide (all doses) ver-
sus active comparators or dulaglutide (all doses) versus 
placebo (Additional file  1: Table S3). Furthermore, no 
significant differences were observed when comparing 
dulaglutide dose (1.5 or 0.75 mg) versus placebo or dula-
glutide dose versus all comparator therapy (active and 
placebo) (Additional file 1: Table S3).
Results of additional endpoints analyses
No significant differences were observed between the 
two treatment groups for the risk of experiencing all-
cause mortality (HR 0.50; 95  % CI 0.18, 1.38), compos-
ite 3-component MACE, or heart failure requiring 
Table 4 Time-to-event analysis of the primary cardiovascular (CV) endpoint and individual components—all randomized 
patients (ITT population)
AWARD Assessment of Weekly AdministrRation of LY2189265 (dulaglutide) in Diabetes, CV cardioavascular, HR hazard ratio, MACE major adverse CV event, MI 
myocardial infarction
a Calculated from a stratified Cox Proportional Hazards regression model: response = treatment. Strata = studies; all Phase 2 studies formed one stratum, AWARD-3 
and AWARD-5 formed one stratum. 2-sided p value to be compared to an alpha level of 0.0198 for test of superiority
b Death from CV causes is defined as a death resulting from an acute MI, sudden cardiac death, death due to heart failure, death due to stroke, and death due to other 
CV causes









Primary 4-component MACE endpoint 25 (1.18) 26 (0.67) 0.57 (0.30, 1.10) 0.046
 Death from CV causesb 5 (0.24) 3 (0.08) 0.35 (0.07, 1.87) 0.119
 Nonfatal MI 14 (0.66) 9 (0.23) 0.35 (0.13, 0.95) 0.014
 Nonfatal stroke 4 (0.19) 12 (0.31) 1.61 (0.42, 6.20) 0.411
 Hospitalization for unstable angina 6 (0.28) 3 (0.08) 0.28 (0.05, 1.46) 0.054
Exposure (event specific person-years follow-up) 2211.31 3926.90 – –
Incidence rate per 100 person-years 1.13 0.66 – –
Fig. 1 Time to first primary 4-component MACE. A Kaplan–Meier plot (with estimated HR [98.02 % CI] and p value) illustrating the time in weeks 
from randomization to the first occurrence of any of the 4 components of the primary endpoint measure
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hospitalization (Table  5). However, there was a signifi-
cant difference between the treatment groups for the 
6-component MACE endpoint (HR 0.57; 95  % CI 0.37, 
0.90; p = 0.016) and the time to coronary revasculariza-
tion endpoint (HR 0.44; 95  % CI 0.21, 0.92; p =  0.029). 
No other significant differences were observed between 
the 2 treatment groups.
Subgroup analysis
The results of the subgroup analysis for the ITT popula-
tion indicated that there was no treatment by subgroup 
interaction and use of dulaglutide resulted in a consistent 
effect across subgroups (data not shown). The HR point 
estimate was <1.0 for all subgroups tested (favoring dula-
glutide) except for tobacco use (HR 1.38), however, this 
effect was not significant (95 % CI 0.41, 4.58).
Overall CV adverse events post‑baseline (regardless 
of adjudication)
As a sensitivity analysis, AE preferred terms were used 
to identify certain categories of CV AEs including coro-
nary artery disease, angina, atrial fibrillation, MI, stroke 
Fig. 2 Forest plot of the primary 4-component MACE endpoint by stratum. A comparison of the primary analysis results (HR [98.02 % CI]) in each 
stratum (study or combinations of studies by which the primary analysis was stratified) with the overall result. Numbers of CV events per each treat-
ment group (Dula/Comparators) are indicated in the parentheses in the y-axis under Stratum
Table 5 Time-to-event analysis of other cardiovascular (CV) endpoints—all randomized patients (ITT population)
AWARD Assessment of Weekly AdministrRation of LY2189265 (dulaglutide) in Diabetes, CV cardioavascular, HR Est estimated hazard ratio, MACE major adverse CV 
event, MI myocardial infarction
a Calculated from a stratified Cox Proportional Hazards regression model: response = treatment. Strata = studies. All Phase 2 studies form one stratum, AWARD-3 and 
AWARD-5 form one stratum. When the total number of outcomes is <10, survival analysis is not performed. Instead when the total number of outcomes is <10 and ≥5, 
Mantel–Haenszel odds ratio and p value by Cochran–Mantel–Haenszel test are reported; When the total number of outcomes is <5, ratio and p-value are not reported
b Composite endpoint of death from CV causes, nonfatal MI, or nonfatal stroke
c Composite endpoint of death from CV causes, nonfatal MI, nonfatal stroke, hospitalization for unstable angina, coronary revascularization, or heart failure requiring 
hospitalization









All cause mortality 8 (0.38) 7 (0.18) 0.50 (0.18, 1.38) 0.181
3-Component MACE endpointb 21 (0.99) 23 (0.59) 0.60 (0.33, 1.08) 0.090
6-Component MACE endpointc 37 (1.74) 39 (1.00) 0.57 (0.37, 0.90) 0.016
Heart failure requiring hospitalization 2 (0.09) 7 (0.18) 2.02 (0.41, 9.88) 0.378
Coronary revascularization 16 (0.75) 13 (0.33) 0.44 (0.21, 0.92) 0.029
 Percutaneous coronary intervention 14 (0.66) 11 (0.28) 0.43 (0.19, 0.95) 0.036
 Coronary artery bypass grafting 2 (0.09) 2 (0.05)
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or transient ischemic attack, heart failure, coronary 
revascularization, and carotid revascularization. Propor-
tions of patients with ≥1 CV AE, reported post-baseline 
regardless of adjudication, were comparable between the 
dulaglutide (8.6 %) and the comparators (9.1 %) groups. 
No significant differences were observed in any category 
between the two groups (data not shown).
Discussion
In consideration of the substantial risk for CV events in 
persons with diabetes, regulatory agencies have required 
rigorous assessment of CV safety for new diabetic medi-
cations [7, 8]. Although, data from final CV outcome 
studies are still limited for the GLP-1 class, retrospective 
and pre-specified CV meta-analyses support continued 
clinical use of this class while awaiting confirmatory CV 
outcome data. Currently, only one GLP-1 RA (lixisena-
tide) has reported CV outcome study (ELIXA) results. 
This study showed that treatment of patients with a prior 
CV event with lixisenatide does not alter the risk for CV 
events [25].
CV meta‑analysis results for dulaglutide and other 
GLP‑1RAs
This CV meta-analysis included data from 9 controlled 
dulaglutide clinical studies with different comparators, 
background medications, and covering a broad spec-
trum of the T2D population. The baseline demograph-
ics and CV risk characteristics were comparable between 
the dulaglutide and comparator group. However, prior 
MI at baseline was slightly higher for the dulaglutide 
group compared to the comparator group (3.4 vs. 2.4 %, 
p = 0.049), an effect that would not be expected to intro-
duce favorable bias for dulaglutide.
Overall, this CV meta-analysis suggests that treatment 
with dulaglutide was not associated with an increase in 
the risk of experiencing a MACE endpoint compared 
with comparator therapies. The incidence of the 4-com-
ponent MACE in the dulaglutide group over time was 
consistently lower than the comparator group (Fig.  1). 
The results of the dulaglutide CV meta-analysis are con-
sistent with other GLP-1 RAs CV meta-analyses data. 
Retrospective post hoc CV meta-analyses demonstrated 
that treatment with shorter-acting GLP-1 RAs (liraglu-
tide or exenatide) did not increase the risk of MACE in 
patients with T2D [26, 27]. Recent pre-specified CV 
meta-analyses of prospectively adjudicated events also 
suggest that treatment with the longer-acting GLP-1 
RAs, albiglutide and taspoglutide, does not increase the 
risk of MACE in patients with T2D [28, 29].
Evaluation of individual component endpoints demon-
strated no significant difference between dulaglutide and 
comparators for risk of death from CV causes, non-fatal 
stroke, or hospitalization for unstable angina. The inci-
dence for non-fatal stroke was numerically higher in the 
dulaglutide group compared to the comparator group, 
but with a HR 98.02 % CI that ranged from 0.42 to 6.20. 
On the other hand, the relative risk of experiencing a 
nonfatal MI was significantly lower with the dulaglutide 
group compared with the comparator group (estimated 
HR: 0.35; adjusted 98.02  % CI [0.13, 0.95; p  =  0.014]). 
However, the total number of events was small and there-
fore, the interpretation of these results should be done 
with caution.
Additional endpoints including the 3-component 
MACE and the 6-component MACE also show results 
consistent with results of the primary measure, indicat-
ing that treatment with dulaglutide does not increase the 
risk for MACE whether defined narrowly (3-component 
MACE) or broadly (6-component MACE). Evaluation 
of individual component endpoints showed a significant 
decrease in the risk for the combined coronary revascu-
larization endpoint (HR 0.44; 95  % CI [0.21, 0.92]). No 
significant difference was observed for the heart failure 
requiring hospitalization endpoint wherein the estimated 
HR was 2.02 and the 95  % CI was [0.41, 9.88]. Further-
more, additional analyses conducted to examine the 
primary 4-component MACE endpoint in the PP and 
completers population, different dulaglutide doses (0.75 
and 1.5  mg), and subgroup analyses are all consistent 
with the outcome of the primary analysis observed in all 
randomized patients.
The incidence for major CV events (3-component, 
4-component, and 6-component MACE) ranged from 
0.59 to 1.00  % in the dulaglutide group compared to 
0.99–1.74  % in the comparator group. This incidence 
rate of MACE events is consistent with rates observed 
in recent CV meta-analyses, which evaluated liraglutide, 
albiglutide, taspoglutide, saxagliptin, and vildagliptin 
[26, 28–31]. Incidence rates per 100 person-years for all 
major CV endpoints (the primary 4-component MACE) 
were lower in the dulaglutide group compared with the 
comparators group (0.66 vs. 1.13, respectively).
Cardiovascular effects of GLP‑1 RAs
Pre-clinical and recent human data indicate that GLP-1 
RAs may play a cardioprotective role via reduction in 
myocardium infarct size, improving endothelial func-
tion, and vasodilation [32–35]. However, another study 
showed that chronic treatment with liraglutide for 
14 weeks did not affect endothelial function [36] indicat-
ing that this may be limited to acute effect. Recent clinical 
data indicate that GLP-1 RAs may alter other modifiable 
CV risk factors such as body weight, blood pressure, or 
lipids [32, 37] potentially leading to reduction in mac-
rovascular risk [38]. It is unknown if these effects would 
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prevent CV events, this hypothesis remains to be con-
firmed in long-term CV outcomes studies.
Potential alteration of CV risk factors by dulaglutide or 
other anti‑hyperglycemic treatments, effects of long‑term 
glycemic control, and the need for long‑term data
In all of the 9 Phase 2 and Phase 3 studies included in 
this meta-analysis, treatment with dulaglutide improved 
glycemic control compared to placebo or active compara-
tors [14–23]. Consistent with the GLP-1 RAs’ mecha-
nism of action, treatment with dulaglutide also has been 
associated with alterations of other additional parameters 
that may be implicated in modifying CV risk including 
lower risk of hypoglycemia [39], body weight loss [39], 
and a small decrease in SBP [17]. Although T2D is an 
established risk factor for macrovascular disease, sev-
eral studies demonstrated that intensive glycemic control 
only resulted in an insignificant slight decrease in CV 
endpoints [40, 41]. However, a recent placebo-controlled 
study in patients with T2D at high risk for CV events 
demonstrated that a lower rate of 3-component MACE 
was observed when empagliflozin was added to standard 
care compared to placebo [42]. Although rates of MI and 
stroke were similar between the two treatment groups, 
empagliflozin-treated patients had significantly lower 
rates of CV-related mortality (3.7 vs. 5.9 % in the placebo 
group; 38  % relative risk reduction), hospitalization for 
heart failure (2.7 and 4.1  %, respectively; 35  % relative 
risk reduction), and all-cause mortality (5.7 and 8.3  %, 
respectively; 32 % relative risk reduction). In addition to 
glycemic efficacy, treatment with empagliflozin has been 
also associated with body weight loss, diuretic effect, and 
a decrease in blood pressure [42], effects that may lead 
to an overall lowering of CV risk. Furthermore, long-
term follow-up data after intensive glycemic control in 
patients at early stage of T2D showed significant decrease 
in MI and all-cause mortality [10], indicating that early 
glycemic control may play a significant role in modu-
lating long-term CV outcomes and delaying diabetes-
related macrovascular complications. The recent 10-year 
long-term follow-up from the Veteran Affairs Diabetes 
Trial (VADT) study provides additional evidence that 
the CV benefits from the initial intensive glucose control 
(median of 5.6 years) is also observed for patients with a 
long duration of T2D (mean of 11.6–12 years) [43]. After 
nearly 10 years of follow-up, patients in the VADT trial 
who were randomized to 5.6  years of intensive glucose 
control had a significantly lower risk (17  % reduction; 
p =  0.04) of having a major CV event than those given 
standard therapy. Therefore, early treatment and long-
term follow up data may be helpful in the evaluation of 
the potential CV benefit related to the glycemic effects of 
GLP-1 RAs.
Strengths and limitations of this CV meta‑analysis
Among strengths of this CV meta-analysis is the inclu-
sion of a broad population that is representative of the 
general T2D population. This meta-analysis included 
patients at different stages of T2D, with a mean duration 
of diabetes ranging from 2.6 to 12.7 years and with multi-
ple CV risk factors [14–23]. Although this CV meta-anal-
ysis suggests that dulaglutide treatment is not associated 
with excess CV risk, limitations of CV meta-analyses in 
general include the relatively short treatment duration. 
In addition, inclusion of a diverse population at differ-
ent stages of T2D, while appropriate for evaluation of 
CV safety in patients with different CV risk factors, may 
not enable evaluation of potential CV benefits due to the 
limited number of patients at earlier stages of T2D and 
the relatively short-term follow up. It is also important to 
note that patients with a recent history of clinically signif-
icant and potentially unstable CV disease were excluded 
from the dulaglutide clinical trial program. For example, 
patients with congestive heart failure (mainly NYHA 
class III or IV), or certain recent CV events including 
MI or stroke, were excluded from most studies. In addi-
tion, patients with eGFR < 60 mL/min/1.73 m2 were also 
excluded from most studies. Therefore, certain popula-
tions with high CV risk may have been excluded from 
the overall population included in this CV meta-analysis, 
which is consistent with most other development pro-
grams [26–29]. Accordingly, the low rate of CV events 
observed in the Phase 2 and 3 T2D populations is a com-
mon limitation for these CV meta-analyses in general.
Conclusions
This CV meta-analysis suggests that treatment of 
patients with T2D with once-weekly dulaglutide for up 
to 104  weeks does not increase the risk for CV events. 
In addition, all sensitivity analyses and additional end-
points consistently suggest that dulaglutide does not 
increase the risk for CV events. Definitive data regard-
ing the assessment of effects of long-term treatment with 
dulaglutide on CV risk will be provided by the currently 
ongoing, large CV outcome Researching CV Events with 
a Weekly Incretin in Diabetes (REWIND) study.
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